Education
About Us
Working with TipRanks
Follow Us
Biovica International AB Class B (DE:9II)
FRANKFURT:9II
RESEARCH TOOLSreports
9II Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.03 - €0.22
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€16.34M
Enterprise Value€48.69M
Total Cash (Recent Filing)€24.41M
Total Debt (Recent Filing)€4.65M
Price to Earnings (P/E)―
Beta0.70
Next Earnings
Sep 11, 2025EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding275,289,060
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.05Price Target Upside66.67% Upside
Rating ConsensusHold
Number of Analyst Covering0
Biovica International AB Class B News
9II FAQ
What was Biovica International AB Class B’s price range in the past 12 months?
Biovica International AB Class B lowest stock price was €0.03 and its highest was €0.22 in the past 12 months.
What is Biovica International AB Class B’s market cap?
Biovica International AB Class B’s market cap is €16.34M.
When is Biovica International AB Class B’s upcoming earnings report date?
Biovica International AB Class B’s upcoming earnings report date is Sep 11, 2025 which is in 4 days.
How were Biovica International AB Class B’s earnings last quarter?
Biovica International AB Class B released its earnings results on Jun 18, 2025. The company reported -€0.017 earnings per share for the quarter, beating the consensus estimate of -€0.026 by €0.008.
Is Biovica International AB Class B overvalued?
According to Wall Street analysts Biovica International AB Class B’s price is currently Undervalued.
Does Biovica International AB Class B pay dividends?
Biovica International AB Class B does not currently pay dividends.
What is Biovica International AB Class B’s EPS estimate?
Biovica International AB Class B’s EPS estimate is >-0.01.
How many shares outstanding does Biovica International AB Class B have?
Biovica International AB Class B has 275,289,060 shares outstanding.
What happened to Biovica International AB Class B’s price movement after its last earnings report?
Biovica International AB Class B reported an EPS of -€0.017 in its last earnings report, beating expectations of -€0.026. Following the earnings report the stock price went down -25%.
Which hedge fund is a major shareholder of Biovica International AB Class B?
Currently, no hedge funds are holding shares in DE:9II
Company Description
Biovica International AB Class B
Biovica International AB (publ), a biotechnology company, develops and commercializes blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in Sweden and internationally. It primarily focuses on breast cancer. The company develops DiviTum, a biomarker assay that measures the activity of the enzyme thymidine kinase-1 in blood serum or cell cultures. It serves cancer institutes, pharmaceutical companies, and collaborative groups. The company was incorporated in 2008 and is headquartered in Uppsala, Sweden.
Technical Analysis
Alzinova AB
―
Biosergen AB
―
Nanologica AB
―
Lipigon Pharmaceuticals AB
―
NextCell Pharma AB
―